Compare Endeavour Silver Corp (EXK) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Neurocrine Biosciences Inc — how do they compare? Endeavour Silver Corp trades at $8.68 (market cap $2.54B), while Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.7× Endeavour Silver Corp's market cap, and Endeavour Silver Corp is more actively traded (7,077,330 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EXK | NBIX | |
|---|---|---|
Market Cap | $2.54B | $14.36B |
Volume | 7,077,330 | 1,237,180 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $185.50 |
52-Week Low | $7.07 | $123.10 |
Typical Hold Time | 25 Days | 23 Days |
Enterprise Value | $2.54B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.32, down 4.04% today, amid a bearish technical signal. The company reported mixed Q2 2026 earnings, matching estimates with $0.15 EPS, but showed strong revenue growth and improved profitability in 2026. Recent news highlights operational progress at Terronera and Kolpa mines, though temporary disruptions occurred. Analyst consensus remains strongly bullish with a $10.50 price target.
Outlook is cautiously optimistic driven by production growth and favorable metal prices, but risks include operational disruptions and high valuation multiples. The stock offers potential upside from current levels if execution continues, but volatility from commodity prices and mine-specific issues persists.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
